MEDIAN Technologies Obtains "Innovative Company" Accreditation From OSEO (the French State Innovation Agency) and is Now Eligible for Tax-Efficient Investments by FCPI Closed-End Funds

SOPHIA ANTIPOLIS, NICE, France, November 29, 2010 /PRNewswire/ --

- The Company Provides Innovative FDA-Cleared and CE-Marked Lesion Management Solutions (LMSs) for Cancer Diagnosis and Follow-up.

MEDIAN Technologies, the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, today announced that it had obtained "Innovative Company" accreditation from OSEO (the French state innovation agency). This accreditation enables innovation-focused French investment funds (Fonds Communs de Placement dans l'Innovation) to invest in MEDIAN Technologies and enjoy a number of fiscal advantages.

MEDIAN Technologies has ISO 13485 certification - the internationally recognized quality standard for the medical device industry. The company's LMSs gained FDA approval in 2007 and a class IIa CE mark was awarded in 2010. The LMSs are used by key opinion leaders in over 102 centres in Europe, the USA and (most recently) Australia.

"Receiving OSEO Innovative Company accreditation emphasizes MEDIAN Technologies' focus on innovation and proves the relevance of our software solutions and services. In fact, our solutions provide the pharmaceutical industry and physicians with essential tools based on new-generation biomarkers, which help detect cancerous lesions early and optimise patient follow-up", commented MEDIAN Technologies' Chairman and CEO Fredrik Brag.

Whilst medical imaging is an important tool, standard methods for image interpretation do not enable all lesions to be detected and optimally monitored over time. MEDIAN Technologies offers the pharmaceutical industry and the medical world a number of integrated LMSs which help interpret medical images and thus improve the diagnosis and monitoring of cancer patients. The LMS software automatically quantifies the lesions and allows the flexible, effective management of lesion-related information. In combination with high levels of automation and standardization, the LMS uses biomarker identification to assist with lesion detection, interpretation, quantification and monitoring over time.

MEDIAN Technologies is targeting the oncology clinical trial market, its primary market, and the cancer patient care market.

For more information about MEDIAN Technologies, visit: http://www.mediantechnologies.com

    Press contacts

    MEDIAN Technologies
    Fredrik Brag, CEO
    +33-492-90-65-82
    [email protected]

    ALIZE RP
    Caroline Carmagnol
    +33-6-64-18-99-59 // +33-1-42-68-86-43
    [email protected]

SOURCE MEDIAN Technologies